Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records for Orforglipron

22 records for Orforglipron, of which 6 are published trials.

Showing 0 records on this page

Records

22 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
ATTAIN-1OrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Moderate
ATTAIN-2OrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Not rated
ACHIEVE-1OrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Not rated
ACHIEVE-2OrforglipronPhase 3ReportedRandomised, double-blind, active-controlled—2025Not rated
ATTAIN-1-REGIONAL-JPprogramme recordOrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Very low
ATTAIN-2-ELDERLYprogramme recordOrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Very low
ACHIEVE-1-REGIONAL-JPprogramme recordOrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Very low
ACHIEVE-2-ELDERLYprogramme recordOrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Very low
ATTAIN-2-OLEprogramme recordOrforglipronPhase 3ReportedSingle-arm open-label—2025Very low
ACHIEVE-1-BODY-COMPprogramme recordOrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Very low
ACHIEVE-2-OLEprogramme recordOrforglipronPhase 3ReportedSingle-arm open-label—2025Very low
ACHIEVE-1-QOLprogramme recordOrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Very low
ACHIEVE-2-ADHERENCEprogramme recordOrforglipronPhase 3ReportedObservational—2025Very low
ACHIEVE-2-BIOMARKERprogramme recordOrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2025Very low
ORFO-PH2-OBESITYOrforglipronPhase 2ReportedRandomised, double-blind, placebo-controlled2722023Moderate
ORFO-PH2-T2DOrforglipronPhase 2ReportedRandomised, double-blind, placebo-controlled3832023Moderate
ORFO-PH2-OBESITY-REGIONAL-JPprogramme recordOrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2023Very low
ORFO-PH2-T2D-HEPATIC-IMPprogramme recordOrforglipronPhase 1ReportedPhase 1 ascending dose—2023Very low
ORFO-PH2-T2D-DDIprogramme recordOrforglipronPhase 1ReportedRandomised crossover—2023Very low
ORFO-PH2-OBESITY-QOLprogramme recordOrforglipronPhase 2ReportedRandomised, double-blind, placebo-controlled—2023Very low
ORFO-PH2-T2D-PKprogramme recordOrforglipronPhase 1ReportedPhase 1 ascending dose—2023Very low
ORFO-PH2-OBESITY-REGIONAL-CNprogramme recordOrforglipronPhase 3ReportedRandomised, double-blind, placebo-controlled—2023Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.